NEW YORK (TheStreet) -- Shares of Johnson & Johnson (JNJ) are slightly higher this morning after it was reported that the company will fast track the development of a new combination vaccine regimen against Ebola amid a race to combat the worst outbreak of the deadly disease on record, Bloomberg reports.
J&J said it will collaborate with Denmark-based biotech company Bavarian Nordic and the National Institute of Allergy and Infectious Diseases. and they will work toward starting a clinical trial in humans early next year.
Must Read: 50 Stocks Hedge Funds Love
TheStreet Ratings team rates JOHNSON & JOHNSON as a Buy with a ratings score of A+. TheStreet Ratings Team has this to say about their recommendation:
"We rate JOHNSON & JOHNSON (JNJ) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, growth in earnings per share and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results."
Highlights from the analysis by TheStreet Ratings Team goes as follows: